What I Learned at Harvard Medical School about Prednisone

On the second day of a prestigious event at Harvard Medical School, the spotlight turned to a topic often overlooked in mainstream medical discussions: the complexities of prednisone withdrawal. Rheumatology experts from leading institutions—including Massachusetts General Hospital, Brigham and Women’s Hospital, and Johns Hopkins—shared their insights on managing chronic inflammatory conditions with corticosteroids, especially prednisone.

Yet, amidst the clinical perspectives, a critical concern emerged: the real-world struggles patients face when tapering off prednisone.

Watch now!

The Patient Experience: Pain, Confusion, and Uncertainty

Data from a survey of over 250 patients with conditions like polymyalgia rheumatica (PMR) revealed a recurring dilemma—patients frequently struggle to determine whether their returning pain stems from a flare-up of their disease or from withdrawal symptoms. This blurred line leaves many uncertain, anxious, and unsupported.

This concern was posed to the panel of rheumatologists at Harvard, seeking clarity. Surprisingly, the dominant response was dismissive: if symptoms return during tapering, it must be the disease flaring—not withdrawal. This perspective underscored a worrying gap between patient experiences and medical interpretation.

The Terminology Debate: Adrenal Insufficiency vs. Withdrawal Syndrome

When first encountering PMR and prednisone withdrawal as a pharmacist, I often heard the term “adrenal insufficiency” used to describe withdrawal symptoms. However, this label can be misleading. True adrenal insufficiency refers to the body’s inability to produce enough cortisol—a life-threatening condition. Prednisone withdrawal, on the other hand, mirrors withdrawal from other substances like alcohol or opioids. The body adapts to prednisone, and sudden changes can trigger a cascade of symptoms.

Despite this distinction, many rheumatologists still use the terms interchangeably. One clinician acknowledged withdrawal but quickly reframed it as adrenal insufficiency, suggesting only severe symptoms like hypotension or hypoglycemia would qualify. Yet patients report fatigue, muscle aches, low mood, and a host of symptoms that fall outside those definitions—yet still cause substantial distress.

The Clinical Approach: Gaps in Support

Some rheumatologists advised waiting a week before adjusting prednisone dosages if patients felt unwell after a taper. But is it reasonable to let patients suffer for a week without intervention?

Consider the case of a patient whose dose was reduced from 5 mg to 4 mg and experienced significant discomfort. After multiple attempts, the patient was told to persist. Was this due to a PMR flare, adrenal insufficiency, or prednisone withdrawal? Without proper terminology and awareness, even clinicians struggle to answer confidently.

Placebo and nocebo effects were also discussed—could the expectation of withdrawal cause symptoms? Possibly. But that only reinforces the need for compassion, communication, and personalized care.

The Problem with Cortisol Testing

Another issue raised was cortisol testing. Some clinicians rely on cortisol levels to assess adrenal function during tapering. But any prednisone dose suppresses natural cortisol production, making these tests unreliable. Research shows cortisol testing should only be conducted three weeks after stopping prednisone entirely—otherwise, the results can be misleading and provide false reassurance or unnecessary concern.

A Call for Greater Awareness

One of the most concerning takeaways from the Harvard discussions was the apparent lack of recognition of steroid withdrawal syndrome among leading experts. Many conflated it with adrenal insufficiency, while others dismissed it entirely.

Yet for patients, this distinction matters. It shapes how they’re treated, supported, and understood.

There is an urgent need for research that clearly defines and differentiates between:

• PMR flare-ups
• Steroid withdrawal syndrome
• True adrenal insufficiency

Only then can clinicians offer targeted support and patients find relief without unnecessary suffering.

Moving Forward: Advocating for Patients

The best approach to managing prednisone withdrawal may be as simple as returning to the lowest effective dose that eases symptoms. Tapering should be gradual, personalized, and empathetic. Patients shouldn’t feel blamed for struggling—they need doctors who recognize withdrawal syndrome as a valid, treatable challenge.

There’s still much to learn about the long-term use of prednisone. One study noted that 40% of rheumatoid arthritis patients remain on prednisone long-term, despite its risks and the medical community’s desire to reduce dependency.

This conversation must continue—not just in academic circles but among patients, caregivers, and advocates. Only through open dialogue and ongoing research can we better navigate the complexities of prednisone therapy.